Ganciclovir
Catalog No.S1878 Synonyms: RS-21592, BW-759
Molecular Weight(MW): 255.23
Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Cited by 3 Publications
1 Customer Review
-
Effect of ganciclovir on viral DNA accumulation (A,B) and induction of TGF-β1 production after human cytomegalovirus infection in human trabecular meshwork cells (C). Cells were harvested at 5 day post-infection at a high multiplicity of infection (MOI 1) under the treatment with different concentrations of ganciclovir (GAN). Treatment with 10 μmol of ganciclovir significantly decreased the viral DNA accumulation (p < 0.001) (A,B). However, treatment with ganciclovir did not affect the TGF-β production using a TGF-β1 luciferase bioassay. Results are expressed as the mean +/− standard deviation of three different experiments.
Sci Rep, 2017, 7: 43349. Ganciclovir purchased from Selleck.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
Biological Activity
| Description | Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In vitro |
Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: (1) a deoxyguanosine kinase induced by CMV-infected cells; (2) guanylate kinase; and (3) phosphoglycerate kinase. [1] Ganciclovir is sufficient to induce cell death in most bystander cells cocultured with HSV-tk-expressing cells. [2] Ganciclovir significantly reduces DNA synthesis in the transformed cells, whereas Ganciclovir has little effect on DNA synthesis in the nontransformed cells. Ganciclovir exhibits a concentration-dependent reduction in the rate of elongation into mature DNA. [3] Ganciclovir induces cell cycle arrests rather than direct chemical effect on HSVtk-transduced B16F10 melanoma cells. [4] Ganciclovir produces only weak inhibition of DNA synthesis. Ganciclovir-treated cells accumulate in early S-phase and remained there until cell death, suggesting that ganciclovir incorporation in the DNA template is important for cytotoxicity. [5] Ganciclovir-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. Ganciclovir-provoked DNA instability is likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. [6] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Data |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vivo | Antiviral drug ganciclovir (GCV) inhibits the proliferation of microglia in experimental autoimmune encephalomyelitis (EAE). GCV attenuates neuroinflammation and does not significantly restrain the peripheral immune response[7]. |
Protocol
| Cell Research: |
+ Expand
|
|---|---|
| Animal Research: |
+ Expand
|
Solubility (25°C)
| In vitro | DMSO | 27 mg/mL warmed (105.78 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. |
2mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 255.23 |
|---|---|
| Formula | C9H13N5O4 |
| CAS No. | 82410-32-0 |
| Storage | powder |
| in solvent | |
| Synonyms | RS-21592, BW-759 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03586284 | Not yet recruiting | Cytomegalovirus Anterior Uveitis | University of California San Francisco|Hwang Pacific Foundation|Khon Kaen University|King Chulalongkorn Memorial Hospital|National Taiwan University|Francis I. Proctor Foundation | October 2019 | Phase 2|Phase 3 |
| NCT03586284 | Not yet recruiting | Cytomegalovirus Anterior Uveitis | University of California San Francisco|Hwang Pacific Foundation|Khon Kaen University|King Chulalongkorn Memorial Hospital|National Taiwan University|Francis I. Proctor Foundation | October 2019 | Phase 2|Phase 3 |
| NCT03699254 | Not yet recruiting | Transplantation Infection|Cytomegalovirus Infections | Maimónides Biomedical Research Institute of Córdoba|Instituto de Salud Carlos III | April 2019 | Phase 3 |
| NCT03699254 | Not yet recruiting | Transplantation Infection|Cytomegalovirus Infections | Maimónides Biomedical Research Institute of Córdoba|Instituto de Salud Carlos III | April 2019 | Phase 3 |
| NCT03576898 | Not yet recruiting | Uveitis Anterior|Cytomegalovirus Infections | Francis I. Proctor Foundation|National Taiwan University|Chulalongkorn University|Khon Kaen University | January 2019 | Phase 2|Phase 3 |
| NCT03576898 | Not yet recruiting | Uveitis Anterior|Cytomegalovirus Infections | Francis I. Proctor Foundation|National Taiwan University|Chulalongkorn University|Khon Kaen University | January 2019 | Phase 2|Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
